News stories about ZIOPHARM Oncology (NASDAQ:ZIOP) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ZIOPHARM Oncology earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.0244952393774 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:

ZIOPHARM Oncology (NASDAQ ZIOP) opened at $4.49 on Thursday. ZIOPHARM Oncology has a 52-week low of $4.03 and a 52-week high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.13). The business had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $1.66 million. The company’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the business earned ($0.11) EPS. equities research analysts expect that ZIOPHARM Oncology will post -0.54 EPS for the current year.

A number of brokerages have recently commented on ZIOP. BidaskClub cut shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. ValuEngine cut shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Zacks Investment Research raised shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a research note on Friday, November 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $9.50 price objective on shares of ZIOPHARM Oncology in a research note on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $12.58.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/11/23/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-ziopharm-oncology-ziop-stock-price.html.

In other news, CEO Laurence James Neil Cooper acquired 6,440 shares of the firm’s stock in a transaction on Wednesday, November 8th. The shares were bought at an average price of $4.68 per share, for a total transaction of $30,139.20. Following the acquisition, the chief executive officer now owns 1,083,731 shares of the company’s stock, valued at approximately $5,071,861.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 10.40% of the company’s stock.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Insider Buying and Selling by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.